- Conditions
- Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss
- Interventions
- CGF166
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 4
- States / cities
- Kansas City, Kansas • Baltimore, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced May 21, 2026, 7:20 PM EDT